Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 9, 2024 | Bladder Cancer
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer Jul 7, 2023 | Bladder Cancer
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer Jun 29, 2023 | Bladder Cancer
QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC) Jun 15, 2022 | Bladder Cancer
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Mar 16, 2022 | Bladder Cancer
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Apr 16, 2020 | Bladder Cancer, Merkel Cell Carcinoma, Non-Small Cell Lung Cancer